

SCHEDULE 8

Consequential provision

PART 2

Amendment of secondary legislation

Amendment of the Health Service Products (Provision and Disclosure of Information) Regulations 2018

15. In regulation 29(4) of the Health Service Products (Provision and Disclosure of Information) Regulations 2018 ^{M1}—

- (a) in the definition of “notifiable presentation”—
 - (i) insert “ UK ” before “marketing authorisation”, and
 - (ii) omit from “other than” to the end;
- (b) in the definition of “designated producer” insert “ UK ” before “marketing authorisation”; and
- (c) in the definition of “marketing authorisation” insert “ UK ” before “marketing”.

Commencement Information

I1 Sch. 8 para. 15 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, **Sch. 5 para. 1(1)**), see [reg. 1](#)

Marginal Citations

M1 [S.I. 2018/677](#).

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Paragraph 15.